Cargando…

Impaired cardiac and peripheral hemodynamic responses to inhaled β(2)-agonist in cystic fibrosis

BACKGROUND: Pulmonary system dysfunction is a hallmark of cystic fibrosis (CF) disease. In addition to impaired cystic fibrosis transmembrane conductance regulator protein, dysfunctional β(2)-adrenergic receptors (β(2)AR) contribute to low airway function in CF. Recent observations suggest CF may al...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Iterson, Erik H., Karpen, Stephen R., Baker, Sarah E., Wheatley, Courtney M., Morgan, Wayne J., Snyder, Eric M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560914/
https://www.ncbi.nlm.nih.gov/pubmed/26341519
http://dx.doi.org/10.1186/s12931-015-0270-y
_version_ 1782388978826084352
author Van Iterson, Erik H.
Karpen, Stephen R.
Baker, Sarah E.
Wheatley, Courtney M.
Morgan, Wayne J.
Snyder, Eric M.
author_facet Van Iterson, Erik H.
Karpen, Stephen R.
Baker, Sarah E.
Wheatley, Courtney M.
Morgan, Wayne J.
Snyder, Eric M.
author_sort Van Iterson, Erik H.
collection PubMed
description BACKGROUND: Pulmonary system dysfunction is a hallmark of cystic fibrosis (CF) disease. In addition to impaired cystic fibrosis transmembrane conductance regulator protein, dysfunctional β(2)-adrenergic receptors (β(2)AR) contribute to low airway function in CF. Recent observations suggest CF may also be associated with impaired cardiac function that is demonstrated by attenuated cardiac output (Q), stroke volume (SV), and cardiac power (CP) at both rest and during exercise. However, β(2)AR regulation of cardiac and peripheral vascular tissue, in-vivo, is unknown in CF. We have previously demonstrated that the administration of an inhaled β-agonist increases SV and Q while also decreasing SVR in healthy individuals. Therefore, we aimed to assess cardiac and peripheral hemodynamic responses to the selective β(2)AR agonist albuterol in individuals with CF. METHODS: 18 CF and 30 control (CTL) subjects participated (ages 22 ± 2 versus 27 ± 2 and BSA = 1.7 ± 0.1 versus 1.8 ± 0.0 m(2), both p < 0.05). We assessed the following at baseline and at 30- and 60-minutes following nebulized albuterol (2.5mg diluted in 3.0mL of normal saline) inhalation: 12-lead ECG for HR, manual sphygmomanometry for systolic and diastolic blood pressure (SBP and DBP, respectively), acetylene rebreathe for Q and SV. We calculated MAP = DBP + 1/3(SBP–DBP); systemic vascular resistance (SVR) = (MAP/Q)•80; CP = Q•MAP; stroke work (SW) = SV•MAP; reserve (%change baseline to 30- or 60-minutes). Hemodynamics were indexed to BSA (Q(I), SV(I), SW(I), CP(I), SVR(I)). RESULTS: At baseline, CF demonstrated lower SV, SV(I), SW, and SW(I) but higher HR than CTL (p < 0.05); other measures did not differ. At 30-minutes, CF demonstrated higher HR and SVR(I), but lower Q, SV, SV(I), CP, CP(I), SW, and SW(I) versus CTL (p < 0.05). At 60-minutes, CF demonstrated higher HR, SVR, and SVR(I), whereas all cardiac hemodynamics were lower than CTL (p < 0.05). Reserves of CP, SW, and SVR were lower in CF versus CTL at both 30 and 60-minutes (p < 0.05). CONCLUSIONS: Cardiac and peripheral hemodynamic responsiveness to acute β(2)AR stimulation via albuterol is attenuated in individuals with CF, suggesting β(2)AR located in cardiac and peripheral vascular tissue may be dysfunctional in this population.
format Online
Article
Text
id pubmed-4560914
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45609142015-09-06 Impaired cardiac and peripheral hemodynamic responses to inhaled β(2)-agonist in cystic fibrosis Van Iterson, Erik H. Karpen, Stephen R. Baker, Sarah E. Wheatley, Courtney M. Morgan, Wayne J. Snyder, Eric M. Respir Res Research BACKGROUND: Pulmonary system dysfunction is a hallmark of cystic fibrosis (CF) disease. In addition to impaired cystic fibrosis transmembrane conductance regulator protein, dysfunctional β(2)-adrenergic receptors (β(2)AR) contribute to low airway function in CF. Recent observations suggest CF may also be associated with impaired cardiac function that is demonstrated by attenuated cardiac output (Q), stroke volume (SV), and cardiac power (CP) at both rest and during exercise. However, β(2)AR regulation of cardiac and peripheral vascular tissue, in-vivo, is unknown in CF. We have previously demonstrated that the administration of an inhaled β-agonist increases SV and Q while also decreasing SVR in healthy individuals. Therefore, we aimed to assess cardiac and peripheral hemodynamic responses to the selective β(2)AR agonist albuterol in individuals with CF. METHODS: 18 CF and 30 control (CTL) subjects participated (ages 22 ± 2 versus 27 ± 2 and BSA = 1.7 ± 0.1 versus 1.8 ± 0.0 m(2), both p < 0.05). We assessed the following at baseline and at 30- and 60-minutes following nebulized albuterol (2.5mg diluted in 3.0mL of normal saline) inhalation: 12-lead ECG for HR, manual sphygmomanometry for systolic and diastolic blood pressure (SBP and DBP, respectively), acetylene rebreathe for Q and SV. We calculated MAP = DBP + 1/3(SBP–DBP); systemic vascular resistance (SVR) = (MAP/Q)•80; CP = Q•MAP; stroke work (SW) = SV•MAP; reserve (%change baseline to 30- or 60-minutes). Hemodynamics were indexed to BSA (Q(I), SV(I), SW(I), CP(I), SVR(I)). RESULTS: At baseline, CF demonstrated lower SV, SV(I), SW, and SW(I) but higher HR than CTL (p < 0.05); other measures did not differ. At 30-minutes, CF demonstrated higher HR and SVR(I), but lower Q, SV, SV(I), CP, CP(I), SW, and SW(I) versus CTL (p < 0.05). At 60-minutes, CF demonstrated higher HR, SVR, and SVR(I), whereas all cardiac hemodynamics were lower than CTL (p < 0.05). Reserves of CP, SW, and SVR were lower in CF versus CTL at both 30 and 60-minutes (p < 0.05). CONCLUSIONS: Cardiac and peripheral hemodynamic responsiveness to acute β(2)AR stimulation via albuterol is attenuated in individuals with CF, suggesting β(2)AR located in cardiac and peripheral vascular tissue may be dysfunctional in this population. BioMed Central 2015-09-05 2015 /pmc/articles/PMC4560914/ /pubmed/26341519 http://dx.doi.org/10.1186/s12931-015-0270-y Text en © Van Iterson et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Van Iterson, Erik H.
Karpen, Stephen R.
Baker, Sarah E.
Wheatley, Courtney M.
Morgan, Wayne J.
Snyder, Eric M.
Impaired cardiac and peripheral hemodynamic responses to inhaled β(2)-agonist in cystic fibrosis
title Impaired cardiac and peripheral hemodynamic responses to inhaled β(2)-agonist in cystic fibrosis
title_full Impaired cardiac and peripheral hemodynamic responses to inhaled β(2)-agonist in cystic fibrosis
title_fullStr Impaired cardiac and peripheral hemodynamic responses to inhaled β(2)-agonist in cystic fibrosis
title_full_unstemmed Impaired cardiac and peripheral hemodynamic responses to inhaled β(2)-agonist in cystic fibrosis
title_short Impaired cardiac and peripheral hemodynamic responses to inhaled β(2)-agonist in cystic fibrosis
title_sort impaired cardiac and peripheral hemodynamic responses to inhaled β(2)-agonist in cystic fibrosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560914/
https://www.ncbi.nlm.nih.gov/pubmed/26341519
http://dx.doi.org/10.1186/s12931-015-0270-y
work_keys_str_mv AT vanitersonerikh impairedcardiacandperipheralhemodynamicresponsestoinhaledb2agonistincysticfibrosis
AT karpenstephenr impairedcardiacandperipheralhemodynamicresponsestoinhaledb2agonistincysticfibrosis
AT bakersarahe impairedcardiacandperipheralhemodynamicresponsestoinhaledb2agonistincysticfibrosis
AT wheatleycourtneym impairedcardiacandperipheralhemodynamicresponsestoinhaledb2agonistincysticfibrosis
AT morganwaynej impairedcardiacandperipheralhemodynamicresponsestoinhaledb2agonistincysticfibrosis
AT snyderericm impairedcardiacandperipheralhemodynamicresponsestoinhaledb2agonistincysticfibrosis